Introduction

Day by day the medicines we know are becoming less effective because of the ability of microorganisms to resist the effects of the medications that were once used to kill them [Table 1]. This ability of the microorganisms is known as antimicrobial resistance (AMR) [Graph 1]. Because of this, the medications have become ineffective and the microorganisms persist for a longer time in the body, and the risk of the spread of the infections and diseases increases and threatens our ability to cure even the common infections. This may result in prolonged illness, disability, and even death [Graph 2]. And without effective antimicrobials, medical procedures and major surgeries also become very risky. In addition, AMR increases the cost of healthcare as stays in the hospitals will be longer and more intensive care will be required. The global health threats of AMR rose to a crescendo and is putting the gains of the Millennium Development Goals and Sustainable Development Goals at peril.[3]

Centers for Disease Control and Prevention (CDC), USA categorized antibiotic-resistant bacteria into three levels [Table 2]:

Concerning: Bacteria belonging to this classification have the threat of antibiotic resistance as “low.” There may or may not be multiple options of therapeutics for the infections of bacterial resistance. These bacteria usually cause severe illness. To monitor these categorical threats, outbreak responses or rapid incidents are required.

Serious: These are significant threats. For various reasons like low or declining domestic incidences or reasonable availability of therapeutic agents, they may not be considered urgent but on a long run, the threats will worsen to turn urgent due to the lack of prevention activities and public health monitoring.

Urgent: The antibiotic resistance threats belonging to this category result in high consequences. Significant risks across various criteria have been attached to these bacteria. These might have the potential to be widespread due to lack of public attention that may identify infections and limit transmission.[4]
Factors that Cause AMR

- Increase in AMR is linked with the amount of the antibiotic prescribed, number of doses missed, and inappropriate and unnecessary prescribing of antibiotics which happen maybe because sometimes patients insist physicians for antibiotics and the physicians prescribe them as they do not have time to explain why they are not needed.\[23,\] 24\]
- Lower antibiotic concentrations\[25\] and longer duration of treatment\[26\] contribute to the increase of AMR.
- Underlying diseases in the healthcare setup such as mechanical ventilation and poor hygiene by hospital staff have also been associated with the spread of resistant organisms.\[27\]
- AMR raise the crescendo when counterfeit medications with subtherapeutic concentrations of antibiotics are used.\[28\]
- Some of the pharmaceutical companies release large amounts of antibiotics in the form of waste due to inappropriate wastewater treatment which eventually increases AMR.\[29\]
- Antibacterial components and antiseptics may also be contributing to AMR.
- Inappropriate use of antibiotics in animal husbandries is also found to be an underlying contributor to the emergence and spread of antibiotic-resistant microbes.\[30\]
- Resistance toward antibiotics sometimes is also natural. These genes that gain resistance are called as environmental resistomes. These genes may be transferrable from non-pathogenic to pathogenic microorganisms which may lead to antibiotic resistance.\[31\]
- It has been found that heavy metals and other pollutants may also be contributing to this global public health hazard.\[32\]

Global Overview of Antimicrobial Resistance

In U.S., at least 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result every year [Table 3].\[33\] In the E.U., 33000 deaths due to antibiotic-resistant bacteria are reported every year.\[34\]

To combat AMR, new drugs are being made or combinations of already existing drugs are being used [Table 4].\[35\]

Indian Scenario

India also carries the burden of AMR, including the highest number of MDR-TB.\[36\] Antimicrobial-resistant microbes have also been found in various animals other than humans like cows, buffaloes, fishes, shrimps, shellfishes, crabs, etc. Even natural resources like water bodies are not safe as antimicrobial-resistant bacteria and their genes have also been found in some of the water sources of India.\[37\]

In India, resistance toward fluoroquinolones, carbapenem, and colistin is found to be high among Gram-negative and Gram-positive bacteria [Table 5]. High resistance toward even the newer antimicrobials like carbapenems and faropenem has been reported.\[38\] Studies have reported high resistance toward fluoroquinolones and cephalosporinsins (third generation) pathogens such as Salmonella typhi, Shigella, Pseudomonas, and Acinetobacter.

It has been estimated that more than 50,000 newborns will die from sepsis due to pathogens being resistant to first-line antimicrobials. It is thought that neonates and elderly will be affected worse. It is estimated that more than two million deaths will occur in India due to AMR by the year 2050.\[39\] About 29% of isolated S. aureus in 2008 were methicillin resistant which by 2014, has reached 47%.\[40\] In addition, since 2011 MDR-yeast has also been reported in India. In another study conducted in 2015, researchers found AMR among Enterobacter cloacae and Morganella morganii in people residing in Bural, a semi-urban community in Chandigarh.\[41\] Around 17% to 75% of the Vibrio cholerae have been found to be resistant toward tetracycline.\[42\] Between 2004 and 2007, E. coli samples showed 73%, 59%, and 75% of rate of resistance to naladixic acid, co-trimoxazole, and ampicillin, respectively.\[43\] Also from 2008 to 2013, resistance of E. coli to cephalosporins (third generation) has increased from 70% to 83%, whereas resistance of fluoroquinolone has increased from 78% to 85%, and carbapenems resistance increased from 10% to 13%.\[44\]

From 2008 to 2014, the rate of resistance toward fluoroquinolones in S. typhi was found to be increased from 8% to 28%. In addition, S. typhi are becoming nalidixic acid resistant as use of other quinolones is increasing. But in 2014, the rate of S. typhi resistance toward ampicillin and co trimoxazole was found to be decreasing. 11% of the Enterococcus faecium isolates were found to be vancomycin resistant.\[45\] From 2002 to 2009, K. pneumoniae...
associated carbapenem resistance has significantly increased from 2% to 52%. In addition, the fluoroquinolone resistance had increased from 57% to 73%. However, the resistance rate of K. pneumoniae isolates toward cephalosporins (third generation) had decreased from 90% to 80%. A study found that 48% of the bacteria (Gram-negative) in the milk of buffalo and cow in West Bengal were detected to be extender spectrum beta lactamase (ESBL) producers and in Gujarat, 47.5% were oxytetracycline resistant. Also among the bacteria (Gram-positive) isolated from the same milk samples, 2.4% of S. aureus in West Bengal were vancomycin resistant, while in Karnataka, 21.4% S. aureus were MRSA. In Maharashtra, 48% of the Enterobacteriaceae isolated from the fish gut of Tilapia were producing ESBL. The rate of ESBL-producing Enterobacteriaceae in Odisha, Madhya Pradesh, and Punjab was found to be 9.4%, 33.5%, and 87%, respectively. In Kerala, V. cholerae and V. parahaemolyticus found in shrimps, crabs, and shellfish were found to be totally resistant to ampicillin, ceftazidime resistance also ranged from 67% to 96% but were found to be susceptible to chloramphenicol. Another study showed the presence of MDR Salmonella species in Bihar and West Bengal being resistant to ciprofloxacin, gentamicin, and tetracycline.

Antimicrobial-resistant microbes have been found in water sources too. All of the samples of E. coli isolated from Kaveri in Karnataka were found to be resistant toward cephalosporins (third generation). The ground and surface water used for drinking along with recreational purposes in central India, Kashmir, Sikkim, and Hyderabad have been reported with 17%, 7%, 50%, and 100% rate of third-generation resistant E. coli, respectively. The rate of cephalosporin (third generation) resistant E. coli in domestic water alone, waste along with hospital effluent, and hospital effluent alone was found to be 25%, 70%, and 95%, respectively. The ESBL producers were 17.4% among bacteria (Gram-negative) isolated from Yamuna and Ganga.

Table 1: Some of the recent occurrences of antimicrobial-resistant microbes and the antimicrobials they are resistant to

| Microorganism                        | Antimicrobial Resistance toward | Year  |
|--------------------------------------|---------------------------------|-------|
| Staphylococcus                       | Penicillin                      | 1940  |
| Shigella                             | Tetracycline                    | 1959  |
| Staphylococcus                       | Methicillin                     | 1962  |
| Pneumococcus                         | Penicillin                      | 1965  |
| Streptococcus                        | Erythromycin                    | 1968  |
| Enterococcus                         | Gentamicin                      | 1979  |
| Enterobacteriaceae                   | Cefazidime                      | 1987  |
| Enterococcus                         | Vancomycin                      | 1987  |
| Pneumococcus                         | Levofloxacin                    | 1996  |
| Enterobacteriaceae                   | Imipenem                        | 1998  |
| Extensively drug-resistant tuberculosis (XDR-TB) | Isoniazid, Rifampicin, Fluoroquinolones, and many more of the third-line injectable drugs. | 2000(7) |
| Staphylococcus                       | Linezolid                       | 2001  |
| Staphylococcus                       | Vancomycin                      | 2002  |
| Pan-Drug Resistant (PDR)- Acinetobactor | All Cephalosporins and inhibitor combinations, Fluoroquinolones, Aminoglycosides, Carbapenems, Polymyxins. | 2004/05(1) |
| PDR-Pseudomonas                      | Penicillins, Cephalosporins, Carbapenems, Monobactams, Quinolones, Aminoglycosides, and Polymyxins. | 2004/05(1) |
| Escherichia coli                     | Third-generation cephalosporin-resistant | 2007(9) |
| Neisseria gonorrhoeae                | Ceftriaxone                     | 2009  |
| Klebsiella pneumoniae                | Carbenapem, Colistin           | 2009(7) |
| Staphylococcus                       | Ceftaroline                     | 2011(8) |
| Neisseria gonorrhoeae                | Azithromycin                    | 2011(9) |
| Multi-Drug Resistant Tuberculosis (MDR-TB) | Rifampicin, Isoniazid, Pyrazinamide | 2012(9) |
| Salmonella paratyphi                 | Ampicillin, Cefotaxime, Ceftazidime, Ceftriaxone, Nalidixic acid, Aztreonam, Trimethoprim/sulfamethoxazole | 2013(9) |
| Escherichia coli                     | Carbenapem                      | 2015(9) |
| Enterococcus faecalis                | Vancomycin                      | 2015(9) |
| Plasmodium falciparum                | Artemisinin-based combination therapies (ACTs) | 2016(7)(1) |
| Salmonella typhi                     | Fluoroquinolones, Ampicillin, Chloramphenicol, Trimethoprim-sulfamethoxazole, Third-generation cephalosporins | 2016(7)(8) |
| New Delhi metallo-beta-lactamase (NDM) type carbapenemase-producing organisms (CPOs) | β-lactam antibiotics(9) | 2017(14) |
| Clostridium difficile                | Aminoglycosides, Lincomycin, Tetracyclines, Erythromycin, Clindamycin, Penicillins, Carbapenems, Fluoroquinolones(9) | 2017(14) |
Chandra, et al.: Antimicrobial resistance for antibiotics

Measures Taken to Overcome AMR

Some of the approaches for combating AMR are:

- Educating people about AMR.
- Educating people about the rational use of antimicrobials.
- Controls of substandard and counterfeit antimicrobials.
- Inducements such as developing new vaccines and drugs.
- Usage of alcohol-based hand cleansers for hands.[63]
- 72 h after the symptoms resolve, antibiotics can be safely stopped.[64]
- Usage of antibiotics with short course along with regular reevaluation with the doctor is necessary. The course must be stopped if no signs of clinical infection are seen as most of the time individuals do not complete the full course.
- Increasing awareness among the nurses and other health care providers is necessary as they are in direct contact with the patients and eventually being responsible for infection spread or control of AMR.[64]
- The standards of drug advertising and promotions should be followed by pharmaceutical companies. Moreover, action toward pharmaceutical companies that encourage inappropriate use of antimicrobials should be taken.[66]
  - Minimized antimicrobial usage in animals, improved sanitization along with the regulated provision of probiotics or supplements in vaccination and feed to control common animal diseases need to be administered.[67]
  - Collective national and international academic networks are necessary to identify new categories of antibiotics along with diagnostic technologies.
  - Providing incentives for the development of new antimicrobials to pharmaceutical companies.[66]

India

In 2013, surveillance networks of AMR were started by the Indian Council of Medical Research and in 2014, the National Centre for Disease Control also started an AMR surveillance network to know the approximate extent of AMR. In 2015, these two organizations along with CDC started assessing the already existing IPC practices in India to formulate new guidelines for preventing hospital-acquired infections.[68] The National Health Policy, 2017 calls for a rapid standardization of guidelines soliciting antibiotic use and limiting the use of antibiotics. In addition, OTC (over the counter) medications, banning or restricting the use of antibiotics as growth promoters in animal livestock, and pharmacovigilance including prescription audits inclusive of antibiotic usage in the hospital and community should be taken care of.[69] Other policies that were created to deal with AMR are as follows.

Table 3: Deaths attributable to AMR by 2050

| Continent  | Number of deaths |
|------------|------------------|
| Asia       | 4,730,000        |
| Africa     | 4,150,000        |
| Europe     | 390,000          |
| North America | 317,000   |
| Oceania    | 22,000           |
| South America | 392,000  |

Table 2: Categorization of antibiotic-resistant bacteria into three levels by Center for Disease Control and Prevention (CDC), USA.[16]

| Category                    | Microorganisms                        | Antimicrobial Resistance toward                                                                 |
|-----------------------------|---------------------------------------|--------------------------------------------------------------------------------------------------|
| Concerning Threats          | Vancomycin-resistant *Staphylococcus aureus* | Vancomycin                                                                                       |
|                             | Erythromycin-resistant *Group A Streptococcus* | Erythromycin                                                                                   |
|                             | Clindamycin-resistant *Group B Streptococcus* | Clindamycin                                                                                     |
|                             | Multidrug-resistant *Acinetobacter*     | All cephalosporins and inhibitor combinations, Fluoroquinolones, Aminoglycosides[69]           |
| Serious Threats             | Drug-resistant *Campylobacter*          | Fluoroquinolones[7]                                                                             |
|                             | Fluconazole-resistant *Candida*         | Fluconazole                                                                                     |
|                             | Vancomycin-resistant *Enterococci* (VRE) | Vancomycin                                                                                      |
|                             | Multidrug-resistant *Pseudomonas aeruginosa* | Imipenem, Ceftazidime, Ciprofloxacin, Tobramycin[69]                                            |
|                             | Drug-resistant *Salmonella typhimurium* | Ampicillin, Trimethoprim-sulfamethoxazole, Chloramphenicol, Fluoroquinolones, Ceftriaxone, Azithromycin[69] |
|                             | Drug-resistant *Shigella*               | Sulphonamides, Tetracycline, Chloramphenicol, Ampicillin, Co-Trimoxazole[69]                   |
|                             | Methicillin-resistant *Staphylococcus aureus* (MRSA) | Methicillin                                                                                     |
|                             | Drug-resistant *Streptococcus pneumonia* | Penicillin, Erythromycin, Trimethoprim-sulfamethoxazole, Tetracycline, Chloramphenicol, Fluoroquinolones[7] |
| Urgent Threats              | *Clostridium difficile*                | Aminoglycosides, Lancomycin, Tetracyclines, Erythromycin, Clindamycin, Penicillins, Cephalosporins, Fluoroquinolones[7] |
|                             | Carbapenem-resistant *Enterobacteriaceae* (CRE) | Carbapenem                                                                                      |
|                             | Drug-resistant *Neisseria gonorrhoeae*[20] | Sulfonamides, Penicillins, Cephalosporins, Tetracyclines, Macrolides, Fluoroquinolones[22]     |
|                             | *Methicillin-resistant Staphylococcus aureus* (MRSA) |                                                                                                  |
|                             | *Drug-resistant Streptococcus pneumonia* |                                                                                                  |
|                             | *Carbapenem-resistant Enterobacteriaceae* (CRE) |                                                                                                  |
|                             | *Drug-resistant Neisseria gonorrhoeae*[20] |                                                                                                  |

Table 2: Categorization of antibiotic-resistant bacteria into three levels by Center for Disease Control and Prevention (CDC), USA.[16]
Antibiotics that work
Third‑generation Cephalosporins, Fluoroquinolones, Aminoglycosides, Imipenem, Ceftazidime, Penicillins, First‑, second‑, and third‑generation

Antibiotics that do not work
Vancomycin, Ceftriaxone, Co‑trimoxazole, Third‑Generation Penicillin, Erythromycin, Trimethoprim, Isoniazid, Rifampicin, Fluoroquinolones, and any of the three second‑line injectable drugs

Table 4: Drugs that work and do not work on certain antibiotic‑resistant microorganisms

| Microorganism                        | Antibiotics that do not work                                                                 | Antibiotics that work                                                                 |
|--------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| MRSA                                 | B‑lactam antibiotics                                                                        | Vancomycin, Teicoplanin, Daptomycin, Linezolid[29]                                     |
| VRE                                  | Vancomycin                                                                                 | Linezolid, Dalfopristin, Daptomycin, Tigecycline, Telavancin[29]                        |
| *Streptococcus pneumoniae*           | Penicillin, Erythromycin, Trimethoprim‑sulfamethoxazole[21]                                 | PCV7, PCV13[41]                                                                        |
| XDR‑TB                               | Isoniazid, Rifampicin, Fluoroquinolones, and any of the three second‑line injectable drugs  | Fewer treatment options are available, and the drugs available are much less effective[3] |
| CRE                                  | All or nearly all available antibiotics                                                     | Aminoglycosides, Polymyxins, Tigecycline, Fosfomycin, and Teicoplanin have been used with some success[41] |
| *Pseudomonas aeruginosa*             | Aminoglycosides, Imipenem, Ceftazidime, Ciprofloxacin, Tobramycin                         | Polymyxins, β‑lactam antibiotics, Carbenapenems[14]                                    |
| ESBL‑producing Enterobacteriaceae     | Penicillins, First‑, second‑, and third‑generation cephalosporins, and Aztreonam            | Carbenapenem, Clavulenic acid[42]                                                     |
| Cephalosporin‑resistant Neisseria     | Cephalosporin, Fluoroquinolones, Tetracyclines, Penicillins, Macrolides                    | Extended Spectrum Cephalosporins (ESCs like Cefixime, Ceftriaxone), Spectinomycin, Azithromycin[22] |
| *Acinetobacter baumannii*            | All penicillins and cephalosporins (including inhibitor combinations), Fluoroquinolones, Aminoglycosides | Colistin, Tigecycline[4]                                                              |
| Non‑Typhoidal Salmonella              | Ampicillin, Chloramphenicol, Co‑trimoxazole, Sulphonamides, Tetracycline                    | Ciprofloxacin, Cefotaxime, Ceftriaxone, Cefoperazone, Aztreonam, Azithromycin[10]     |

Table 5: AMR microorganisms found in India and the antimicrobials they are resistant to

| AMR Microorganisms | Antibiotic Resistance Toward                                                                 |
|--------------------|---------------------------------------------------------------------------------------------|
| *Escherichia coli* | Third‑generation Cephalosporins, Fluoroquinolones, Carbapenem, Ampicillin, Naladixic acid, Co‑trimoxazole[9,39] |
| *Salmonella species* | Ciprofloxacin, Gentamicin, Tetracycline, Ceftriaxone, Co‑trimoxazole, Ampicillin, Naladixic acid, Fluoroquinolones, Third Generation Cephalosporins[40,41] |
| *Vibrio cholera*   | Ampicillin, Tetracycline, Chloramphenicol, Ceftazidime[42,43]                               |
| *Vibrio parahaemolyticus* | Ampicillin, Chloramphenicol, Ceftazidime[43]                                                |
| *Staphylococcus aureus* | Vancomycin, Methicillin[39,52]                                                              |
| *Shigella species* | Ceftriaxone, Co‑trimoxazole, Third Generation Cephalosporins, Fluoroquinolones, Azithromycin, Chloramphenicol, Ampicillin, Naladixic acid[44] |
| *Enterococcus faecium* | Vancomycin[48]                                                                             |
| *Klebsiella pneumoniae* | Carbapenem, Fluoroquinolones, Third‑generation Cephalosporins[49]                         |
| *Acinetobacter baumannii* | Fluoroquinolones, Third Generation Cephalosporins[50]                                      |
| *Pseudomonas aeruginosa* | Fluoroquinolones, Third Generation Cephalosporins[51]                                      |

National Antimicrobial Resistance Policy, India

In 2011, national policy on AMR has been introduced. The objective of this policy is to increase awareness in the emergence of AMR and the factors influencing it. In addition, to establish programs such as antimicrobial rationalized usage and to provide incentives to develop new effective antimicrobial drugs, this policy came into act. This policy concentrates on three categories such as sentinel surveillance, point prevalence, and comprehensive surveillance. Some of the action plans included in the policy are as given below:[70]

• To establish surveillance system of AMR
• Prevention of infections along with respective control measures
• To increase awareness of rational antimicrobial use in all stakeholders.

National Action Plan on Antimicrobial Resistance (NAP‑AMR)

The objective of NAP‑AMR is to combat AMR and contribute to tackle this global health threat. This policy will help establish and strengthen governance mechanisms and volume of stakeholders to decrease the aftermath of AMR in India. The extent of NAP‑AMR primarily emphasizes on resistance in bacteria.

The objectives of the NAP‑AMR are:
1. To define the strategic priorities, key actions, outputs, responsibilities, and indicative timeline and budget to slow the emergence of AMR in India and strengthen the organizational and management structures to ensure intra‑ and inter‑sectoral coordination with a One Health approach;
2. To combat AMR in India through better understanding and awareness of AMR, strengthened surveillance, prevention of emergence and spread of resistant bacteria through infection prevention and control, optimized use of antibiotics in all sectors, and enhanced investments for AMR activities, research, and innovations; and
3. To enable monitoring and evaluation (M and E) of the NAP‑AMR implementation based on the M and E framework.
Chandra, et al.: Antimicrobial resistance for antibiotics

The NAP-AMR has outlined six strategic priorities to tackle this public health challenge and these are to be implemented over 2017–2021. The first 5 strategic priorities of NAP-AMR are aligned with the Global Action Plan on AMR and the sixth strategic priority highlights India’s role in the containment of AMR at the international level and at subnational/state level to ensure action at the ground level. The focus areas of the six strategic priorities of NAP-AMR are:

1. Improve awareness and understanding of AMR through i) effective communication and IEC resources to raise awareness among all stakeholders, including policymakers, general public, and farmers, and ii) education and training to improve the knowledge and behavior of professionals.
2. Strengthen knowledge and evidence through surveillance by strengthening laboratories for evidence-informed policy-making in human, animal, food, and environment sectors. And by surveillance of AMR for evidence-informed policy-making in human, animal/food, and environment sectors.
3. Reduce the incidence of infection through effective infection prevention and control in: i) Healthcare to reduce the burden of infection, ii) Animal health/food to reduce the spread of AMR and antimicrobials through animals and food and, iii) Community and community environment to reduce the spread of AMR and antimicrobials in the community and environment.
4. Optimize the use of antimicrobial agents in health, animals, and food with the help of i) Regulations, access, and surveillance of antimicrobial use to ensure rational use without affecting access to antimicrobials, ii) Antimicrobial stewardship in healthcare to optimize the use of antimicrobials in humans, and iii) Animal health, agriculture to optimize the use of antimicrobials in animal and food sectors.
5. Promote investments for AMR activities, research, and innovations by i) New medicines and diagnostics to ensure availability of effective diagnostics and drugs to treat infections, ii) Innovations to develop alternative approaches to manage infectious diseases, and iii) Financing to ensure sustainable resources for containment of AMR.
6. Strengthen India’s leadership on AMR with i) International collaborations to ensure India’s contributions toward global efforts to contain AMR, ii) National collaborations to facilitate collaborations among vertical disease control programs and national stakeholders, and iii) State level collaborations to ensure action at the ground level against AMR. [71]

Conclusion

One of the most important statistics in the public health sector is that of AMR. The statistical overview of the drug-resistant microbes helps in enhancing people’s knowledge along with helping with discovering new antimicrobials. Different policies give broad guidelines on how to combat the microbes from developing resistance. As mentioned in the review, microbes belonging to different generations which are classified on the basis of bacterial strains of a genus developing resistance are increased in both global and Indian scenario. Hence, to provide insight, this review holds great importance to the respective statistics.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. CDC. About Antimicrobial Resistance. 2018. Available from: www.cdc.gov. Archived from the original on 1 October 2017. Available from: https://www.cdc.gov/drugresistance/about.html. [Retrieved 2015 Oct 30].
2. WHO. Antimicrobial Resistance. 2018. Available from: https://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance. [Last accessed on 2019 Apr 12].
3. CDC. TB Elimination Extensively Drug-Resistant Tuberculosis (XDR TB). 2013. Available From: https://www.cdc.gov/tb/publications/factsheets/drdtb/xdrtb.htm. [Last accessed on 2019 Apr 12].
4. Chandra, Sanchaita S, Singh NP. Multidrug resistant Acinetobacter. J Global Infect Dis [serial online] 2010;2:291-304. Available from: http://www.jgid.org/text.asp?2010/2/3/291/68538. [Last cited on 2019 Oct 21].
5. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulos P, Michalopoulos A, et al. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005;5:24.
6. Cassini A, Högborg LD, Plachouras D, Quattrrocchi A, Hoxha A, Simonsen G5, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect Dis 2018;19:56-66.
7. Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011;55:593-9.
8. Papp JR, Abrams AJ, Nash E, Katz AR, Kirkcaldy RD, Connor NPO, et al. Azithromycin resistance and decreased ceftriaxone susceptibility in Neisseria gonorrhoeae, Hawaii, USA. Emerg Infect Dis 2017;23:830-2.
9. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Med Chem 2014;6:25-64.
10. Mawatari M, Kato Y, Hayakawa K, Morita M, Yamada K, Mezaki K, et al. Salmonella enterica serotype Paratyphi A carrying CTX-M-15 type extended-spectrum beta-lactamase isolated from a Japanese traveller returning from India, Japan, July 2013. Euro Surveill 2013;18 pii=20632. Available from: http://www.eurosurveillance.org/View Article.aspx?ArticleId=20632. [Last accessed on 2019 Apr 12].
11. WHO. WHO Strategy for Malaria Elimination in the Greater Mekong subregion (2015-2030). Available from: https://www.who.int/westernpacific/note ws/commentaries/detail-hq/battling‑malaria‑in‑the‑greater‑mekong‑subregion. [Last accessed on 2019 Apr 12].
12. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK,
et al. Emergence of an extensively drug-resistant salmonella entericaserovartphi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. mBio 2018;9. doi: 10.1128/mBio.00105-18.

13. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602.

14. Government of Canada. Canadian Antimicrobial Resistance Surveillance System-Update 2018: Executive Summary. 2019. Available from: https://www.canada.ca/en/public-health/services/publications/drugs-hea-lth-products/canadian-antimicrobial-resist ance-surveillance-system-2018-report-execute-summary.html. [Last accessed on 2019 Apr 12].

15. Johansen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, et al. Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes 2015;6:1347-60.

16. CDC. Antibiotic Resistance Threats in the United States, 2013. Available From: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. [Last accessed on 2019 Apr 12].

17. Sproston EL, Wimalarathna HML, Sheppard SK. Trends in fluoroquinolone resistance in Campylobacter. Microb Genom 2018;4: doi: 10.1099/mgen.0.000198.

18. Bhatt P, Rath KR, Hazra S, Sharma A, Shete V. Prevalence of multidrug resistant Pseudomonas aeruginosa infection in burn patients at a tertiary care centre. Indian J Burns 2015;23:56-9.

19. Kalra SP, Naithani N, Mehta SR, Swamy AJ. Current trends in the management of typhoid fever. Med J Armed Forces India 2003;59:130-5.

20. Taneja N, Mewara A. Shigellosis: Epidemiology in India. Indian J Med Res [serial online] 2016;143:565-76. Available from: http://www.ijmr.org.in/text.asp?2016/143/5/565/187104. [Last cited on 2019 Oct 21].

21. Karcic E, Aljicevic M, Bektas S, Karcic B. Antimicrobial susceptibility/resistance of Streptococcus pneumoniae. Materia Socio-Medica 2015;27:180.

22. Alirol E, Wi TE, Bala M, Bazzo ML, Chen X-S, Deal C, et al. Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. PLoS Med 2017;14:e1002366.

23. Pechere JC. Patients' interviews and misuse of antibiotics. Clin Infect Dis 2001;33(Suppl 3):S170-3. Epub 2001/08/29. pmid: 11524715.

24. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev 2005. doi: 10.1002/14651858.CD003539.pub2.

25. Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. P T 2015;40:277-83.

26. “Duration of antibiotic therapy and resistance”. NPS Medicinewise. National Prescribing Service Limited trading, Australia. 2013. Archived from the original on 23 July 2015. [Retrieved 2015 22 Jul].

27. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998;42:521-7.

28. “Fake drugs: The global industry putting your life at risk”. Mosaic. 2018. [Retrieved 2018 13 Dec].

29. ScienceDaily. Pharmaceuticals sold in Sweden cause serious environmental harm in India, research shows. ScienceDaily. LLC. 2009. Archived from the original on 4 February 2015. [Retrieved 2015 29 Jan]. Available from: https://www.sciencedaily.com/releases/2009/02/090205083522.htm. [Last accessed on 2019 Apr 12].

30. Aiello AE, Larson EL, Levy SB. Consumer antibacterial soaps: Effective or just risky? Clin Infect Dis 2007;45(Suppl 2):S137-47.

31. Shepherd MJ, Moore G, Wand ME, Sutton JM, Bock LJ. Pseudomonas aeruginosa adapts to octenidine in the laboratory and a simulated clinical setting, leading to increased tolerance to chlorhexidine and other biocides. J Hosp Infect 2018;100:e23-9.

32. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog Glob Health 2016;109:309-18.

33. Wright GD. Antibiotic resistance in the environment: A link to the clinic? Curr Opin Microbiol. 2010;13:589-94.

34. Seiler C, Berendonk TU. Heavy metal driven co-selection of antibiotic resistance in soil and water bodies impacted by agriculture and aquaculture. Front Microbiol 2012;3:399.

35. CDC. Antibiotic/Antimicrobial Resistance (AR/AMR). 2018. Available from: https://www.cdc.gov/drugresistance/index.html. [Last accessed on 2019 Apr 12].

36. The Review on Antimicrobial Resistance (AMR). Chaired by Jim O’Neill (2014). Jointly supported by the UK Government and Wellcome Trust.

37. ISGlobal. The 4 Battlefronts in the War against Antibiotic Resistance. 2016. Available from: https://www.isglobal.org/en/info rm-la-batalla-contra-las-resistencias. [Last accessed on 2019 Apr 12].

38. Schito GC. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect 2006;12(Suppl 1):3-8.

39. Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014;58:734-9.

40. CDC. “Pneumococcal Vaccination: What Everyone Should Know”. 2017. Available from: https://www.cdc.gov/vaccines/vp_d/pneumo/public/index.html. [Last accessed on 2019 Apr 12].

41. Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by Carbapenem-resistant Enterobacteriaceae: An update on therapeutic options. Front Microbiol 2019;10:80.

42. Rawat D, Nair D. Extended-spectrum β-lactamases in gram negative bacteria. J Global Infect Dis 2010;2:263-74.

43. WHO. Global tuberculosis report. 2017. Available from: http://www.who.int/tb/publications/global_report/en/2018. [Last accessed on 2019 Apr 12].

44. Taneja N, Sharma M. Antimicrobial resistance in the environment: The Indianscenario. Indian J Med Res 2019;149:119-28.

45. Gandra S, Klein FY, Pant S, Malhotra-Kumar S, Laxminarayan R. Faropenem consumption is increasing in India. Clin Infect Dis 2016;62:1050-2.

46. CDDEF. The State of the World's Antibiotics, 2015.
Washington DC: Center for Disease Dynamics, Economics and Policy; 2015. Available from: https://cddep.org/wp-content/uploads/2017/06/swa_edits_9.16.pdf. [Last accessed on 2019 Apr 12].

47. Walla K, Ohri VC, Mathai D. Antimicrobial stewardship programme of ICMR. Antimicrobial stewardship programme (AMSP) practices in India. Indian J Med Res 2015;142:130-8.

48. Gupta M, Didwgal G, Bansal S, Kaushal K, Batra N, Gautam V, et al. Antibiotic-resistant Enterobacteriaceae in healthy gut flora: A report from north Indian semiurban community. Indian J Med Res 2019;149:276-80.

49. Holloway K, Mathai E, Sorensen T, Gray T. Community-based Surveillance of Antimicrobial Use and Resistance in Resourcesconstrained Settings: Report on Five Pilot Projects. Geneva: World Health Organization; 2009. [Last accessed on 2017 Apr 15]. Available from: http://apps.who.int/medicinedocs/docum ents/s16168e/s16168e.pdf.

50. CDDEP. ResistanceMap. Washington DC: Center for Disease Dynamics, Economics and Policy; 2015. [2015 Aug 20]. Available from: https://resistancemap.cddep.org. [Last accessed on 2019 Apr 12].

51. Das A, Guha C, Biswas U, Jana PS, Chatterjee A, Samanta I, et al. Detection of emerging antibiotic resistance in bacteria isolated from subclinical mastitis in cattle in West Bengal. Vet World 2017;10:517-20.

52. Bhattacharyya D, Banerjee J, Bandyopadhyay S, Mondal B, Nanda PK, Samanta I, et al. First report on vancomycin-resistant *Staphylococcus aureus* in bovine and caprine milk. Microb Drug Resist 2016;22:675-81.

53. Preethirani PL, Isloor S, Sundareshan S, Nathanalakshmi V, Deepthikiran K, Sinha AY, et al. Isolation, biochemical and molecular identification, and *in vitro* antimicrobial resistance patterns of bacteria isolated from bubaline subclinical mastitis in South India. PLoS One 2015;10:e0142717.

54. Marathe NP, Gaikwad SS, Vaishampayan AA, Rasane MH, Shenouche YS, Gade WN, et al. Mossambicus tilapia (*Oreochromis mossambicus*) collected from water bodies impacted by urban waste carries extended-spectrum beta-lactamas and integron-bearing gut bacteria. J Biosci 2016;41:341-6.

55. Gandra S, Joshi J, Trett A, Lamkang A, Laxminarayan R. Scoping Report on Antimicrobial Resistance in India. Washington, DC: Center for Disease Dynamics, Economics and Policy; 2017. Available from: http://www.dbtindia.nic.in/wp-content/uploads/ScopingreportonAntimicrobialresistanceinIndia.pdf. [Last accessed on 2017 Apr 15].

56. Sudha S, Miricula C, Silverst R, Hath AAM. Prevalence and antibiotic resistance of pathogenic Vibrios in shellfishes from Cochin market. Indian J Geo Mar Sci 2014;43:815-24.

57. Skariyachan S, Mahajanakatti AB, Grandhi NJ, Prasanna A, Sen B, Sharma N, et al. Environmental monitoring of bacterial contamination and antibiotic resistance patterns of the fecal coliforms isolated from Cauvery River, a major drinking water source in Karnataka, India. Environ Monit Assess 2015;187:279.

58. Kumar S, Tripathi V, Garg SK. Antibiotic resistance and genetic diversity in water-borne Enterobacteriaceae isolates from recreational and drinking water sources. Int J Environ SciTechnol 2013;10:789-98.

59. Rather TA, Hussain SA, Bhat S, Shah S, Arshid S, Shahnawaz M. Antibiotic sensitivity of *E. coli* and Salmonella isolated from different water sources in Kashmir, India. Comp Clin Pathol 2013;22:729-31.

60. Poonia S, Singh TS, Tsering DC. Antibiotic susceptibility profile of bacteria isolated from natural sources of water from rural areas of East Sikkim. Indian J Community Med 2014;39:156-60.

61. Akiba M, Senba H, Otagiri H, Prabhasankar VP, Taniyasu S, Yamashita N, et al. Impact of wastewater from different sources on the prevalence of antimicrobial-resistant *Escherichia coli* in sewage treatment plants in South India. Ecotoxicol Environ Saf 2015;115:203-8.

62. Azam M, Jan AT, Haq QM. Bla CTX-M-152, a novel variant of CTX-M-group-25, identified in a study performed on the prevalence of multidrug resistance among natural inhabitants of river Yamuna, India. Front Microbiol 2016;7:176.

63. WHO Guidelines on Hand Hygiene in Health Care. World Alliance for Patient Safety. World Health Organization; 2009. Available from: https://www.who.int/gpsc/5m_toolkits/who_guidelines-handhygiene_summary.pdf. [Last accessed on 2019 Apr 12].

64. McCormack J, Allan GM. A prescription for improving antibiotic prescribing in primary care. BMJ 2012;344:d7955.

65. Moongtui W, Picheansathian W, Senaratana W. Role of nurses in prevention of antimicrobial resistance. Regional Health Forum 2011;1:104-11.

66. WHO Global Strategy for Containment of Antimicrobial Resistance. World Health Organization; 2001. Available from: https://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf. [Last accessed on 2019 Apr 12].

67. Ganguly NK, Arora NK, Chandy SJ, Fairoz MN, Gill JP, Gupta U, et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res 2011;134:281-94.

68. WHO Global Strategy for Containment of Antimicrobial Resistance. World Health Organization; 2016. Available from: http://www.searo.who.int/india/topics/antimicrobial_resistance/amr_containment.pdf?ua=1. [Last accessed on 2019 Apr 12].

69. Ministry of Health & Family Welfare, India. National Health Policy. New Delhi: MoHFW; 2011. Available from: http://cdisco.nic.in/writereaddata/national-healthpolicy.pdf. [Last accessed on 2017 Apr 15].

70. National Policy for Containment of Antimicrobial Resistance, Directorate General of Health Services, Ministry of Health and Family Welfare, India 2017. Available from: http://www.searo.who.int/india/topics/anti microbial_resistance/nap_amr.pdf. [Last accessed on 2019 Apr 12].